Some key points emerging from the COX-2 controversy.
Urquhart
John
J
D052246:Cyclooxygenase 2 Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D007783:Lactones / Q000009:adverse effects* / Q000627:therapeutic use; D009524:Newspapers as Topic / Q000941:ethics; D011358:Product Surveillance, Postmarketing / Q000379:methods / Q000592:standards; D013450:Sulfones / Q000009:adverse effects* / Q000627:therapeutic use; D016896:Treatment Outcome; D014481:United States; D014486:United States Food and Drug Administration / Q000331:legislation & jurisprudence
D052246:Cyclooxygenase 2 Inhibitors; D007783:Lactones; D013450:Sulfones; C116926:rofecoxib